A new antibody-drug conjugate delivers a potent chemotherapy payload directly to triple-negative breast cancer cells while leaving healthy tissue largely unharmed. Triple-negative breast cancer accounts for 10–15% of breast cancer cases globally and is one of the most aggressive forms of the disease. Existing treatments often cause severe side effects, lose effectiveness as tumours develop drug resistance, and offer poor outcomes for patients who have exhausted standard therapies. Spirea Ltd, a University of Cambridge spin-out, has developed a proprietary linker technology that attaches more therapeutic drug to each antibody and incorporates a next-generation payload designed to overcome resistance. Early preclinical results show the conjugate is highly effective in TNBC models, with better tolerability and greater dosing flexibility than current options. If clinical trials confirm these results, the therapy could become a first-in-class treatment for patients with few remaining options. Because the target protein is also overexpressed in melanoma, prostate, and ovarian cancers, the same conjugate could eventually be adapted for other solid tumours. For the NHS, a more effective and less toxic treatment could reduce hospital stays and lower overall cancer care costs.
View original technical description
**The development of a first-in-class cancer therapeutic for difficult-to-treat metastatic Triple Negative Breast Cancer.** Spirea Ltd a cutting-edge spin-out from the University of Cambridge intents on revolutionizing cancer treatment with its pioneering Antibody-Drug Conjugate (ADC) for Triple Negative Breast Cancer (TNBC)---one of the most aggressive and deadly forms of breast cancer. TNBC affects 10-15% of breast cancer patients globally, and existing treatments are often limited by severe toxicity, drug resistance, and poor efficacy. Spirea's breakthrough lies in a proprietary linker technology which allows more therapeutic drug payload to be delivered to the target cancer cell increasing ADC design flexibility to reduce unwanted side-effects. For the first time, we are incorporating a next-generation payload, designed to overcome drug resistance, into our ADCs, offering a first-in-class treatment option for TNBC patients who have exhausted existing therapies. Our technology addresses a critical unmet need, with early preclinical results showing our ADC to be highly effective in a TNBC model , with greater tolerability and dosing flexibility. Beyond TNBC, this ADC has the potential to expand into other solid tumours where the target is overexpressed, including other breast cancers, melanoma, prostate, and ovarian cancers. This project is supported by a strong team of experts in ADC development, bioconjugation, and oncology, alongside leading CRO partners. Together, we aim to deliver a novel ADC therapy that will not only transform treatment outcomes for TNBC patients but also align with NHS goals by reducing cancer treatment time and generating significant healthcare savings. With Innovate UK funding, we will accelerate preclinical validation, paving the way for clinical trials, partnerships with leading pharmaceutical companies, and the next breakthrough in cancer therapeutics.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know